Skip to main content
Clinical Trials/NCT04624945
NCT04624945
Recruiting
Not Applicable

DetectIon of Severe Sepsis In PATients With Neurological haemorrhagE (The DISSIPATE Study)

National University Hospital, Singapore1 site in 1 country150 target enrollmentNovember 25, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
National University Hospital, Singapore
Enrollment
150
Locations
1
Primary Endpoint
To validate the use of APTT CWA and ICIS, as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The research study is to explore novel early predictors and validation of laboratory parameters in the management of sepsis in critically ill patients especially with brain injuries and systemic inflammatory response syndrome (SIRS).

Detailed Description

This is a prospective observational study. 150 subjects with the admission diagnosis of neurological haemorrhage (e.g. subarachnoid haemorrhage, intracerebral haemorrhage etc), admitted to SICU of National University Hospital, Singapore, who are expected to stay for more than 48 hours, will be recruited and enrolled. No adverse events are expected as a result of this study as patients do not deviate from the current standard of care. Frequency of blood sampling will be stipulated at day 1/2/3/4/5 to draw clinical relevance. An additional 0.5 tablespoonful (7.7ml) of blood will be taken daily from each subject as well as residual blood from routine laboratory test blood samples. In total, an additional volume of 2.5 tablespoonful (38.5ml) of blood will be collected from each subject over a period of 5 days. Residual blood refers to any leftover blood samples collected for routine laboratory tests which will be shared and used to carry out additional blood tests. All ICU patients will have arterial lines inserted as part of routine care, so there will not be pain from the blood sampling. In the current study, measurements will be made on the routine laboratory haematology, coagulation and immunoassay analyzers. Research blood parameters that are not usually reported as indicated in the background section will be used for the correlation and association analysis to sepsis. In addition, the study team will also be collecting clinical and demographic data of recruited subjects from medical records for purposes of this study.

Registry
clinicaltrials.gov
Start Date
November 25, 2020
End Date
December 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults 21 years and above
  • Clinical/radiological suspicion or confirmation of neurological haemorrhage

Exclusion Criteria

  • Age below 21 years
  • Prisoners
  • Known pregnancy
  • Do-not-attempt resuscitation status
  • Requirement for immediate surgery
  • Active chemotherapy/neutropenia (Neutrophil count \<1.0 x 109/L)
  • Immuno-compromised
  • Haematological malignancy
  • Treating physician deems aggressive care unsuitable
  • Unable to provide informed consent or comply with study requirements

Outcomes

Primary Outcomes

To validate the use of APTT CWA and ICIS, as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.

Time Frame: SICU stay from day 1 to day 5 through to 2 years of blood test completion

Activated Partial Thromboplastin Time (APTT) clot waveform analysis (CWA) by flow cytometry-based method

Secondary Outcomes

  • To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery.(SICU stay from day 1 to day 5 through to 2 years of blood test completion)

Study Sites (1)

Loading locations...

Similar Trials